EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma

Kotoe Oshima, Takahiro Tsushima iD, Yoshinori Ito, Ken Kato iD

Japanese Journal of Clinical Oncology · 06.04.2024 · 54 (4) · 395-402

DOI: 10.1093/jjco/hyae005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 10.02.2024. Verfasst von Kotoe Oshima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oesophageal squamous cell carcinoma is a common malignancy worldwide. Definitive chemoradiotherapy is the standard treatment for patients with resectable stage oesophageal squamous cell carcinoma who cannot undergo surgery, as well as those with locally advanced unresectable oesophageal squamous cell carcinoma. However, it has several disadvantages such as poor survival, radiation-related toxicities and severe and lethal complications related to salvage treatment for residual or recurrent disease. Numerous clinical trials on chemoradiotherapy have been conducted to confirm the optimal combination of irradiation and chemotherapy. For advanced disease, multimodal treatment strategies including salvage surgery are essential. Palliative chemoradiotherapy is also crucial for dysphagia in locally advanced oesophageal squamous cell carcinoma with or without metastatic lesions. Recently, the synergistic mechanism of radiotherapy combined with immunotherapy has been reported. Early phase clinical trials suggest that a combination of immunotherapy and chemoradiotherapy can improve clinical outcomes with manageable side effects, but further investigations are needed. Here, we reviewed the existing clinical data and current development of chemoradiotherapy combined with immunotherapy in patients with oesophageal squamous cell carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal Squamous Cell CarcinomaEsophageal NeoplasmsHumansChemoradiotherapyCombined Modality TherapyAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

chemoradiotherapyclinical trialsimmunotherapyoesophageal squamous cell carcinoma

Autor:innen und Institutionen

  • Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
  • Department of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Takahiro Tsushima, Ken Kato

Zitieren

APA

Oshima, K., Tsushima, T., Ito, Y., & Kato, K. (2024). Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma. Japanese Journal of Clinical Oncology, 54(4), 395-402. https://doi.org/10.1093/jjco/hyae005

Vancouver

Oshima K, Tsushima T, Ito Y, Kato K. Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma. Japanese Journal of Clinical Oncology. 2024;54(4):395-402. doi:10.1093/jjco/hyae005

BibTeX
@article{Oshima2024,
  author = {Oshima, Kotoe and Tsushima, Takahiro and Ito, Yoshinori and Kato, Ken},
  title = {Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  volume = {54},
  number = {4},
  pages = {395--402},
  doi = {10.1093/jjco/hyae005}
}
Kostenlos starten →